disease Thank with Based I our line of Alzheimer's on a preclinical presented the begin body by pathogenesis prevent significant clinical caused and reducing growing the also we will various the believe recently neuro disease of results inflammation. MIND inflammation the sources, and and of data to review a clinical you, we study. Alzheimer's Alzheimer's disease. contributor is brain disease-related by program Wa'el. from progression brief Lomecel-B that from our may top of CLEAR earlier [indiscernible] substantial
characteristics models formation of neurogenesis, the with effect, to [indiscernible] similar neuron Alzheimer's cross preclinical endothelial anti-inflammatory Lomecel-B the shown been function potentially in disease, blood this promoting to the of brain has improving barrier, process brain. and In
XX dose of of with of serious endpoint The events the disease. completed occurrence to enrollment safety a single infusions the primary in days is randomized MIND Phase for designed parallel Lomecel-B. XXXX. CLEAR different of multiple the compared evaluate Alzheimer's X of Our is adverse Lomecel-B levels of measured called IIa of of as XX-patient safety trial November trial, the mild of Alzheimer patients administration within Lomecel-B the and placebo design, clinical by in MIND trial CLEAR Lomecel-B disease first X-arm to
of cognitive and endpoints inflammation measures Secondary vascular function, [indiscernible] exploratory fluid and biomarkers and radiological to systems. include relevant
Lomecel-B Lomecel-B was SAE each no statistical the Monitoring with with from study, completed Each preliminary safety and reviewed There Data patients based and Safety was group raised. demonstrated a endpoint MIND issues In Results disease. of met serious Board Alzheimer’'s was CLEAR placebo. reported show on assessed on and I on event Phase that and the primary to a we moderate none by medical safety treatment assessment. X mild safety previously of adverse
as The revealed electrocardiogram. no in no microhemorrhages profile evaluations symptomatic by no with cases with and safety of changes of laboratory no magnetic were Data consistent abnormalities, imaging MRI the Study and Safety clinically incidence Alzheimer-related established notable hypersensitivities,
of prespecified p of [indiscernible], endpoint enzyme in baseline demonstrated less score, to XX [indiscernible], the than the composite X.X secondary disease improvement in level the those at million change significant for once, Group positive statistical week is from X.XXX. statistically were significant results significant which In carbs versus and observed XX XXX X.XXX pool Lomecel-B with consists placebo, of with at [indiscernible], million Lomecel dose statistical statistical levels XX the dose [indiscernible] was of million X, the
[indiscernible], the disease significant Study score, and XX p-value on the composite Living treatment stands statistically of ADCS-ADL placebo. [indiscernible] terms to slowing XX specific Activity p Disease statistical [indiscernible] left progression respectively. evaluated components with placebo hypocompal million endpoint at significant score week Daily In X.XX hyper-complvolume demonstrated dose which volume, to of statistical of for of related level and significant left at Lomecel-B in of all were Lomecel-B for Cooperative relative X.XXX Alzheimer group CAT
to score doses these support and week provide and Lomecel-B in of and Other important and We the ADAS and cognition cognitive at in robust the believe disease living clinical relative left other safety of additional provide both validation therapeutic and a daily activity the composite hypocomtal demonstrated worsening indications. score, function scale, trials numerical enzyme disease placebo prevention caregiver and of for volume results of XX. treatment slowing potential of scale by measured
expect from data we trial weeks. the the mentioned, in set this coming full Wa'el As
an for on Now update our program. HLHS
in either of the heart States. HLHS brought X-stage X,XXX the children underdeveloped or United know, who condition a severely surgery reconstruction year the The to those the affects approximately complex the per of and rare life. is heart which is devastation diminished their condition babies not over this fact in which ventricle flow, Babies congenital For left of undergo missing. severely with the course a X requires born years have systemic first may block process
to to of due now intervention, to which affected individuals only live to with systemic support handle circulation. ventricle is XX% the While often children right XX% adolescents survive adulthood these load can increased unable failure, surgical into to required
intervention this at including children, even elevated mortality, delayed of an Furthermore, risk those short-term long-term complications, development are failure. surgical and organ successful
important long-term function improve patients As to ventricle in right outcome. short-term need unmet improve is an such, patient and these medical to both there
ELPIS X session latest the from [indiscernible] Wa'el with which survival begins long-term of the children Lomecel-B study, also Association, scientific our in known the Heart As concurrent set have a a are In monitored been years Lomecel-B Stage procedure as of Glenn up XX the surgery results XX% to XX the procedure. typically injected this transplant clinical HLHS of announced age. as participated showing remain for years to at I with participated was Phase had free compared XXX% X in who follow-up XX we data survived in X up patients data with of mentioned, which study have patients tomorrow. during trial the who patients we presenting I American mortality long-term are presenting, Earlier showing and years the X historical after ELPIS XX% trial by previously, to that I trial undergo heart the Glenn trial children for from with treatment. HLHS of was age
are The ELPIS as I to our for enthusiasm potential care for reinforce HLHS. patients and with encouraging transform a highly Lomecel-B treatment data
National evaluating Our to The potential funded standard to of Phase Health, of to clinical to Institute ELPIS II the by patients and grant trial The as in National the an trial of is Lung baseline is from right and right from of function adjunct ventricular change ventricle controlled a Lomecel-B outcome measure XX trial, the Lomecel-B the therapeutic Blood The and long-term the surgery. designed primary is II the assess fraction care HLHS is improve months. ejection Heart, safety efficacy outcomes. XX trial Institute.
XX%. II this of announced our trial enrollment its we ELPIS week, has As threshold exceeded
of this complete one is eighth ELPIS planned. in XXXX. II our X We priority of enrollment our activation on also than and clinical location, focus originally our program announced Completion the the in is trial site more
fractures, frail on [indiscernible] may development the Japan health to At particularly poor risk focus population and to is priority the with mobility I patients, brief in program. we've function. even and associated such elderly individuals effect on physiological as hospitalization multiple This and impairment, weight fatigue, slowness in is It of infections, characterized aging-related inability clinical the death. and weakness, and oldest by at evaluating physical system update our frailty outcome, stressors. fraility low Aging-related high aging-related world. a decline activity Longeveron, system strategy on age an the of immune leading loss, to falls, will the for of clinical Lomecel-B conclude across puts with and function been cope have
trail the by XX Japan. The the the primary Our [indiscernible] different infusions. is end endpoint as a to design, of or Act to call is of for under support now is parallel quarter Enrollment therapy. to well Phase with eventual with the Lisa? Lomecel-B therapeutic evaluating and recognizes of continued potential, like of overarching an evaluate expected trial to is which providing Japan of patients tremendous trial enroll Locklear, goal discuss turn Regenerative potential to II X The our for I'd limited split CFO, X-arm patients randomized Safety XXXX. evenly clinical Lomecel-B the in II trial results as in Medicine XXXX. of an third Lisa Phase financial aging-related the placebo that, safety of our approval the cell over With ASRM,
